Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained

Affiliations

¹ Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland.
² Hematology/Nephrology, Sandoz Biopharmaceuticals, HEXAL AG, Industriestr. 25, 83607, Holzkirchen, Germany. andriy.krendyukov@sandoz.com.
³ Sandoz Biopharmaceuticals, Sandoz International GmbH, Kundl, Austria.
⁴ Department of Hematology-Oncology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.

Published Erratum

Matti Aapro et al. BioDrugs. 2018 Apr.

. 2018 Apr;32(2):137-138.

doi: 10.1007/s40259-018-0268-3.

¹ Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland.
² Hematology/Nephrology, Sandoz Biopharmaceuticals, HEXAL AG, Industriestr. 25, 83607, Holzkirchen, Germany. andriy.krendyukov@sandoz.com.
³ Sandoz Biopharmaceuticals, Sandoz International GmbH, Kundl, Austria.
⁴ Department of Hematology-Oncology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.

Abstract

Figure 1, HX575 column, 5th box down, which previously read "SC HX575 vs. Eprex^®/Erypo^® 417 patients with CKD-related anemia" as shown here.

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.
Aapro M, Krendyukov A, Schiestl M, Gascón P. Aapro M, et al. BioDrugs. 2018 Apr;32(2):129-135. doi: 10.1007/s40259-018-0262-9. BioDrugs. 2018. PMID: 29417431 Free PMC article. Review.